Thalassaemia is a genetic blood disorder that requires lifelong attention, but modern treatment approaches have transformed what’s possible for people living with this condition—from regular blood transfusions and iron-removing medications to emerging gene therapies that offer new hope for the future.

Understanding How Thalassaemia Is Managed Today

When someone receives a diagnosis of thalassaemia, the main goals of treatment focus on managing anaemia (a condition where the body has too few healthy red blood cells), preventing complications from iron buildup, and supporting normal growth and development. The approach to treatment depends heavily on which type of thalassaemia a person has and how severely it affects their body. Some people with milder forms may need little to no treatment, while those with more serious types require regular medical care throughout their lives.^[1]

Treatment strategies for thalassaemia have come a long way. In the past, severe thalassaemia often led to early death by the twenties or thirties due to heart failure and other complications. Today, with proper care and newer treatments, people with thalassaemia can expect to live into their fifties, sixties and beyond. This improvement comes from better blood screening, more effective treatments for removing excess iron from the body, and in some cases, the possibility of a cure through advanced procedures.^[6]

Medical societies and specialist centres around the world have developed guidelines to help doctors provide the best possible care. These guidelines emphasize the importance of coordinated care from a team of specialists including blood doctors, heart specialists, liver experts, hormone doctors, and others working together. People with thalassaemia benefit most when they receive care at specialized thalassaemia centres where the medical team has deep experience managing this complex condition.^[16]

Standard Treatment Approaches

Blood Transfusions

For many people with moderate to severe thalassaemia, regular blood transfusions form the backbone of treatment. During a blood transfusion, healthy red blood cells from a donor are delivered through a small tube inserted into a vein in the arm. The procedure typically takes one to four hours and is performed in a hospital or clinic setting. These transfusions provide the body with red blood cells containing normal haemoglobin, which helps carry oxygen throughout the body and relieves symptoms of anaemia such as extreme tiredness, breathlessness, and weakness.^[11]

The frequency of transfusions varies depending on the severity of the condition. People with the most serious form, called beta thalassaemia major or Cooley’s anaemia, typically need transfusions every three to four weeks to maintain healthy haemoglobin levels. Those with less severe forms, such as thalassaemia intermedia, may only need occasional transfusions during times when the body is under stress—for example, during infections, pregnancy, or surgery. People with thalassaemia minor or trait usually don’t need transfusions at all because their anaemia is either absent or very mild.^[12]

Blood transfusions are generally safe procedures. Blood screening has significantly reduced the risk of infections being passed through donated blood. However, regular transfusions do create a particular challenge: they cause iron to build up in the body over time, which can lead to serious complications if not addressed.^[10]

Iron Chelation Therapy

Each red blood cell contains haemoglobin, which is an iron-rich protein. When someone receives regular blood transfusions, all that extra iron has nowhere to go—the body has no natural way to remove large amounts of it. The iron accumulates in organs like the heart, liver, and hormone-producing glands, where it can cause damage over time. This condition is called iron overload, and managing it is crucial for preventing life-threatening complications.^[13]

Chelation therapy is the treatment used to remove excess iron from the body. The medicines used in this therapy are called chelating agents, and they work by binding to iron so it can be eliminated through urine or stool. Three main chelating agents are currently available, each with different ways of being taken.^[11]

Desferrioxamine (also called DFO or Desferal) is given as a slow infusion under the skin. A small pump delivers the medication through a thin needle over eight to twelve hours, usually done five or six nights a week. Some people find this schedule challenging to maintain, but it has been used for many years and is effective. Doctors often recommend taking a small amount of vitamin C (no more than 250 milligrams) at the start of the infusion to help increase iron removal.^[13]

Deferiprone (DFP) comes as a tablet or liquid taken three times daily by mouth. This option is more convenient for some people than overnight infusions. It’s sometimes used in combination with desferrioxamine to reduce the number of infusions needed while still effectively removing iron.^[13]

Deferasirox (DFX) is taken once daily as a tablet that can be swallowed or dissolved in water. The once-daily dosing makes it easier for many patients to stick to their treatment plan. Each medication has its own potential side effects, and doctors work with patients to choose the best option based on individual circumstances and preferences.^[10]

Folic Acid Supplementation

Many doctors prescribe folic acid, a B vitamin, to help support red blood cell development in people with thalassaemia. Folic acid assists the body in making new red blood cells. This treatment is usually given alongside other therapies rather than on its own. It’s particularly important because people with thalassaemia may become deficient in this vitamin due to increased red blood cell turnover.^[12]

Surgical Removal of the Spleen

The spleen is an organ that filters blood and removes old or damaged red blood cells. In some people with thalassaemia, the spleen becomes enlarged and overactive, destroying red blood cells too quickly and making anaemia worse. When this happens, doctors may recommend a splenectomy—surgical removal of the spleen. This procedure can reduce the frequency of blood transfusions needed because the body no longer destroys red blood cells as rapidly.^[10]

However, removing the spleen increases the risk of serious infections because the spleen plays an important role in fighting bacteria. People who have had their spleen removed need to take extra precautions, including staying up to date with vaccinations (especially pneumococcal, meningococcal, and influenza vaccines) and sometimes taking daily preventive antibiotics.^[17]

Treatment in Clinical Trials

Gene Therapy: A Potential Cure

One of the most exciting developments in thalassaemia treatment is gene therapy, which aims to correct the genetic problem causing the disease at its source. In January 2024, the U.S. Food and Drug Administration approved a groundbreaking gene therapy called CASGEVY™ (also known as exagamglogene autotemcel or exa-cel) for treating transfusion-dependent beta-thalassaemia in patients aged twelve years and older. This represents the first approved gene therapy for this condition and offers hope for a functional cure.^[12]

The treatment works by taking a patient’s own blood stem cells—special cells from bone marrow that can develop into red blood cells—and modifying them in a laboratory. Scientists use a precise genetic editing technique to alter the cells so they can produce healthy haemoglobin. These modified stem cells are then given back to the patient through a single infusion as part of a blood stem cell transplant. Before receiving the modified cells, patients must undergo high-dose chemotherapy to clear out their existing bone marrow cells, making room for the new, genetically corrected cells to take hold and start producing healthy red blood cells.^[12]

This approach is different from traditional treatments because it addresses the underlying genetic cause rather than just managing symptoms. Early results from clinical trials have shown promising outcomes, with patients experiencing significant reductions in or complete elimination of their need for regular blood transfusions. However, the treatment requires intensive preparation and monitoring, and long-term effects are still being studied as this is a relatively new therapy.

Hematopoietic Stem Cell Transplantation

Another potential cure for thalassaemia is hematopoietic stem cell transplantation (also called bone marrow transplant). In this procedure, a patient receives healthy stem cells from a donor—often a sibling or other family member whose tissue type closely matches the patient’s. These donor stem cells can produce normal haemoglobin and healthy red blood cells, potentially curing the disease.^[13]

The transplant process is intensive and carries significant risks. Patients first receive high doses of chemotherapy or radiation to destroy their existing bone marrow. Then the donor stem cells are infused into their bloodstream, where they travel to the bone marrow and begin producing new blood cells. The process requires several weeks in hospital and months of recovery.^[10]

The main risk is graft versus host disease, a life-threatening complication where the transplanted cells recognize the patient’s body as foreign and attack it. This can affect the skin, liver, digestive system, and other organs. Other risks include infection, bleeding, and organ damage from the conditioning treatment. Because of these serious risks, stem cell transplantation is usually considered most carefully in children with severe thalassaemia who have a well-matched donor and are otherwise in good health. Doctors must weigh the potential for cure against the possibility of severe complications or death from the procedure itself.^[6]

Luspatercept: A Newer Medication

Clinical trials have been exploring additional medications that work differently from traditional treatments. Luspatercept is a medication that has shown promise in clinical studies for thalassaemia. Rather than providing red blood cells through transfusion or removing iron, luspatercept works by helping the body’s own bone marrow produce more mature, functional red blood cells. The drug targets specific molecular pathways involved in red blood cell development.^[7]

In clinical trials, some patients taking luspatercept experienced a reduction in their transfusion needs. The medication is given as an injection under the skin, typically every three weeks. Researchers are continuing to study its long-term effectiveness and safety, as well as which patients benefit most from this treatment approach.

Hydroxyurea

Hydroxyurea is a medication originally used for other blood conditions that has been studied in thalassaemia, particularly beta thalassaemia. It works by increasing the production of fetal haemoglobin (a type of haemoglobin normally made before birth that can partly compensate for the lack of normal adult haemoglobin). By boosting fetal haemoglobin levels, hydroxyurea can reduce anaemia and potentially decrease transfusion requirements in some patients, particularly those with thalassaemia intermedia.^[7]

The medication is taken as a daily pill. Clinical trials have shown variable results, with some patients responding well while others show little benefit. Doctors typically monitor patients closely when starting hydroxyurea to assess its effectiveness and watch for side effects, which can include low blood counts and gastrointestinal symptoms.

Participation in Clinical Trials

Clinical trials for thalassaemia are ongoing in many countries, including the United States, Europe, and other regions. These trials test new medications, improved chelation therapies, refined transplant protocols, and innovative gene therapy approaches. Trials typically progress through three phases: Phase I studies focus primarily on safety in a small number of people; Phase II studies evaluate whether a treatment appears effective and continue monitoring safety in a larger group; and Phase III studies compare the new treatment with current standard treatments in even larger populations to confirm effectiveness and identify less common side effects.

People interested in participating in clinical trials should discuss options with their thalassaemia care team. Trials have specific eligibility requirements, which may include age limits, disease severity criteria, previous treatment history, and overall health status. Participation in clinical trials provides access to cutting-edge treatments while contributing to research that may benefit future patients.

Most common treatment methods

• Blood transfusions
  • Regular transfusions every 3-4 weeks for beta thalassaemia major to maintain healthy haemoglobin levels
  • Occasional transfusions for thalassaemia intermedia during illness, pregnancy, or surgery
  • Procedure takes 1-4 hours and delivers healthy red blood cells through a vein
  • Most important standard treatment for moderate to severe thalassaemia
• Iron chelation therapy
  • Desferrioxamine (DFO) given as overnight infusion 5-6 times weekly through a pump under the skin
  • Deferiprone (DFP) taken as tablet or liquid three times daily by mouth
  • Deferasirox (DFX) taken once daily as a tablet
  • Removes excess iron from the body to prevent organ damage from iron overload
  • Essential for anyone receiving regular blood transfusions
• Folic acid supplementation
  • B vitamin prescribed to support red blood cell production
  • Usually given alongside other treatments
  • Helps address vitamin deficiency common in thalassaemia patients
• Gene therapy
  • CASGEVY™ (exagamglogene autotemcel) approved in 2024 for transfusion-dependent beta-thalassaemia
  • Uses patient’s own stem cells that are genetically modified in a laboratory
  • Requires high-dose chemotherapy preparation before one-time stem cell infusion
  • Aims to provide a functional cure by correcting the genetic problem
  • Available for patients aged 12 years and older
• Hematopoietic stem cell transplantation
  • Also called bone marrow transplant
  • Uses healthy stem cells from a matched donor, often a sibling
  • Can potentially cure thalassaemia but carries significant risks including graft versus host disease
  • Requires intensive chemotherapy or radiation preparation and lengthy recovery
  • Considered most often for children with severe disease and well-matched donors
• Newer medications in clinical trials
  • Luspatercept helps bone marrow produce more functional red blood cells, potentially reducing transfusion needs
  • Hydroxyurea increases fetal haemoglobin production to partially compensate for missing normal haemoglobin
  • Various clinical trials ongoing in Phase I, II, and III testing safety and effectiveness
• Splenectomy
  • Surgical removal of the spleen when it becomes enlarged and overactive
  • Can reduce frequency of needed transfusions
  • Requires extra infection precautions including vaccinations and sometimes preventive antibiotics

Living Well with Thalassaemia

Beyond medical treatments, several lifestyle factors help people with thalassaemia maintain the best possible health. A healthy, balanced diet is important for everyone, though people with thalassaemia need to pay particular attention to iron in their food. Those receiving regular transfusions should limit foods very high in iron, such as red meat, liver, fortified cereals, and iron-supplemented products, because their bodies already have excess iron from transfusions. However, those with non-transfusion-dependent thalassaemia may have different dietary needs. Drinking tea with meals can help reduce iron absorption from food.^[21]

Regular exercise benefits people with thalassaemia just as it does everyone else, helping strengthen bones, maintain a healthy weight, and improve overall wellbeing. The intensity and type of exercise that’s appropriate depends on individual circumstances. Many people with well-controlled thalassaemia can participate in moderate activities like walking, swimming, cycling, and yoga. Those with joint problems may prefer low-impact options such as water aerobics. It’s important to discuss exercise plans with the medical team to ensure activities are safe and appropriate for each person’s situation.^[17]

Preventing infections is crucial, especially for people who have had their spleen removed, as they are at higher risk for serious bacterial infections. Staying current with vaccinations provides important protection. This includes routine childhood and adult vaccines, annual influenza shots, and special vaccines against pneumococcal bacteria, meningococcus, and Haemophilus influenzae type b. Simple hygiene measures like regular handwashing and avoiding close contact with sick people when possible also help reduce infection risk.^[17]

Most importantly, people with thalassaemia need to stick to their treatment schedules. Regular transfusions and chelation therapy work best when done consistently as prescribed. Missing appointments or skipping doses of chelation medication can lead to dangerous complications. Building good relationships with the healthcare team, family members, and friends creates a support network that makes it easier to manage the demands of treatment over a lifetime.^[17]

Coordinated Care and Monitoring

Successful thalassaemia management requires regular monitoring and coordinated care from multiple specialists. People with thalassaemia should have at least an annual comprehensive assessment at a specialized thalassaemia centre where a team of experts can evaluate all aspects of their health. This team typically includes a blood specialist (haematologist), nurses specializing in thalassaemia care, a liver specialist, a heart specialist, a hormone specialist (endocrinologist), a psychologist, a genetic counsellor, a social worker, and a nutritionist.^[16]

Regular monitoring includes blood tests to check haemoglobin levels and iron stores, heart function tests, liver assessments, hormone level measurements, and bone density scans. Special imaging techniques can measure iron accumulation in organs like the heart and liver, helping doctors adjust chelation therapy to prevent damage. Regular dental care is also important because thalassaemia and its treatments can affect teeth and gums.^[16]

Communication between the specialist centre and local healthcare providers ensures that recommendations are followed and any problems are addressed quickly. This network approach, with everyone working together, provides the best outcomes for people living with thalassaemia throughout their lives.